These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15910595)

  • 1. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.
    Lörinc E; Jakobsson B; Landberg G; Veress B
    Histopathology; 2005 Jun; 46(6):642-8. PubMed ID: 15910595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
    Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
    Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.
    Kaye PV; Haider SA; Ilyas M; James PD; Soomro I; Faisal W; Catton J; Parsons SL; Ragunath K
    Histopathology; 2009 May; 54(6):699-712. PubMed ID: 19438745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
    Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining.
    van der Wel MJ; Duits LC; Pouw RE; Seldenrijk CA; Offerhaus GJA; Visser M; Ten Kate FJ; Biermann K; Brosens LAA; Doukas M; Huysentruyt C; Karrenbeld A; Kats-Ugurlu G; van der Laan JS; van Lijnschoten GI; Moll FCP; Ooms AHAG; van der Valk H; Tijssen JG; Bergman JJ; Meijer SL
    Histopathology; 2018 May; 72(6):1015-1023. PubMed ID: 29314176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment.
    Panjehpour M; Coppola D; Overholt BF; Vo-Dinh T; Overholt S
    Anticancer Res; 2008; 28(1B):485-9. PubMed ID: 18383889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
    Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
    Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
    Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
    Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
    Fortun PJ; Anagnostopoulos GK; Kaye P; James M; Foley S; Samuel S; Shonde A; Badreldin R; Campbell E; Hawkey CJ; Ragunath K
    Aliment Pharmacol Ther; 2006 Mar; 23(6):735-42. PubMed ID: 16556175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.
    Kerkhof M; van Dekken H; Steyerberg EW; Meijer GA; Mulder AH; de Bruïne A; Driessen A; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD;
    Histopathology; 2007 Jun; 50(7):920-7. PubMed ID: 17543082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrow-band imaging with magnification in Barrett's esophagus: validation of a simplified grading system of mucosal morphology patterns against histology.
    Singh R; Anagnostopoulos GK; Yao K; Karageorgiou H; Fortun PJ; Shonde A; Garsed K; Kaye PV; Hawkey CJ; Ragunath K
    Endoscopy; 2008 Jun; 40(6):457-63. PubMed ID: 18459090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities.
    Peters FP; Krishnadath KK; Rygiel AM; Curvers WL; Rosmolen WD; Fockens P; Ten Kate FJ; van Baal JW; Bergman JJ
    Am J Gastroenterol; 2007 Sep; 102(9):1853-61. PubMed ID: 17509033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.
    Walts AE; Lechago J; Bose S
    Am J Surg Pathol; 2006 Jul; 30(7):795-801. PubMed ID: 16819320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
    Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M
    Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sensitivity and inter- and intra-observer variability in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus with enhanced magnification endoscopy.
    Mayinger B; Oezturk Y; Stolte M; Faller G; Benninger J; Schwab D; Maiss J; Hahn EG; Muehldorfer S
    Scand J Gastroenterol; 2006 Mar; 41(3):349-56. PubMed ID: 16497625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 expression in different epithelial types in columnar lined oesophagus indicates varying levels of expanded and aberrant proliferative patterns.
    Olvera M; Wickramasinghe K; Brynes R; Bu X; Ma Y; Chandrasoma P
    Histopathology; 2005 Aug; 47(2):132-40. PubMed ID: 16045773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus.
    Polkowski W; Meijer GA; Baak JP; ten Kate FJ; Obertop H; Offerhaus GJ; van Lanschot JJ
    Anal Quant Cytol Histol; 1997 Jun; 19(3):246-54. PubMed ID: 9196808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.